2.40

1.23% -0.03

After Hours: 2.41 0.01 +0.42%

Century Therapeutics Inc (IPSC)

Overview News Price History Option Chain Financials Discussions Forecast

Century Therapeutics Inc stock is traded at $2.40, with a volume of 1.03M. It is down -1.23% in the last 24 hours and up +12.68% over the past month. Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.

Previous Close:

$2.43

Open:

$2.42

24h Volume:

1.03M

Relative Volume:

0.79

Market Cap:

$432.85M

Revenue:

$109.16M

Net Income/Loss:

$-107.78M

P/E Ratio:

-2.1694

EPS:

-1.1063

Net Cash Flow:

$-95.45M

1W Performance:

-0.41%

1M Performance:

+12.68%

6M Performance:

+166.67%

1Y Performance:

+332.35%

1-Day Range:

$2.31

$2.466

1-Week Range:

$2.285

$2.55

52-Week Range:

$0.435

$3.04

Century Therapeutics Inc Stock (IPSC) Company Profile

Name

Century Therapeutics Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

215-981-4000

Address

25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

IPSC's Discussions on Twitter

Compare IPSC vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IPSC Century Therapeutics Inc	2.40	441.87M	109.16M	-107.78M	-95.45M	-1.1063
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-25-26	Initiated	TD Cowen	Buy
Aug-08-24	Initiated	Rodman & Renshaw	Buy
Aug-28-23	Downgrade	JP Morgan	Overweight → Neutral
Dec-27-22	Initiated	Chardan Capital Markets	Buy
Oct-31-22	Initiated	Guggenheim	Buy
Oct-10-22	Initiated	Canaccord Genuity	Buy
May-23-22	Initiated	H.C. Wainwright	Buy
May-12-22	Initiated	William Blair	Mkt Perform
Jul-13-21	Initiated	BofA Securities	Buy
Jul-13-21	Initiated	JP Morgan	Overweight
Jul-13-21	Initiated	Piper Sandler	Overweight

View All

Century Therapeutics Inc Stock (IPSC) Latest News

Jun 29, 2026

Century Therapeutics, Inc.(NasdaqCM: IPSC) added to Russell 2000 Index - marketscreener.com

Jun 29, 2026

Century Therapeutics, Inc.(NasdaqCM: IPSC) added to Russell 2000 Value Benchmark - marketscreener.com

Jun 29, 2026

Century Therapeutics, Inc.(NasdaqCM:IPSC) added to Russell Microcap Value Benchmark Index - marketscreener.com

Jun 29, 2026

Century Therapeutics, Inc.(NasdaqCM: IPSC) added to Russell Microcap Index - marketscreener.com

Jun 29, 2026

Jun 26, 2026

Century Therapeutics, Inc. Actuals & Estimates (NASDAQ:IPSC) - TradingView

Jun 26, 2026

Enterprise value to EBIT forward of Century Therapeutics, Inc. – NASDAQ:IPSC - TradingView

Jun 26, 2026

Price to earnings forward of Century Therapeutics, Inc. – NASDAQ:IPSC - TradingView

Jun 26, 2026

IPSC Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Jun 25, 2026

Enterprise value to revenue forward of Century Therapeutics, Inc. – NASDAQ:IPSC - TradingView

Jun 25, 2026

Century Therapeutics updates its CAR-T pipeline, shares trade on Nasdaq - AD HOC NEWS

Jun 25, 2026

Jun 23, 2026